{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:36:54Z","timestamp":1767206214955,"version":"build-2238731810"},"reference-count":21,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: The aims of this study were to assess the following: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS). Methods: This multicenter study included 322 patients from eight centers. Univariable and multivariable analyses (MVA) were performed, with the development of pneumonia during venetoclax-based treatment and OS as outcomes. Results: The most common complication was neutropenia (59%). During treatment with venetoclax-based regimens, 66 (20%) patients developed pneumonia\u201450 (23%) patients in the rituximab-plus-venetoclax (R-VEN) group and 13 (16%) patients in the obinutuzumab-plus-venetoclax (O-VEN) group (p = 0.15). Chronic obstructive pulmonary disease (COPD)\/asthma, splenomegaly, elevated creatinine, and anemia &lt; 8 g\/dL were the risk factors for EFS in MVA (HR = 2.08, 95%CI 1.16\u20133.74, p = 0.014; HR 1.73, 95%CI 1.08\u20132.78, p = 0.02; HR 2.13, 95%CI 1.10\u20134.11, p = 0.03, HR 3.58, 95%CI 2.18\u20135.89, p &lt; 0.001, respectively). Relapsed\/refractory (R\/R) CLL patients treated with R-VEN with pneumonia had worse OS than those without (p &lt; 0.001). In patients treated with O-VEN, median OS did not differ between patients with and without pneumonia (p = 0.45). Conclusions: Our real-world study showed that pneumonia during venetoclax treatment occurs more frequently than reported in registration trials and has a negative impact on OS, especially in patients with R\/R CLL who are treated with R-VEN. Neutropenia is not a risk factor for pneumonia.<\/jats:p>","DOI":"10.3390\/cancers16244168","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T10:08:53Z","timestamp":1734343733000},"page":"4168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG)"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-8001","authenticated-orcid":false,"given":"El\u017cbieta","family":"Kalici\u0144ska","sequence":"first","affiliation":[{"name":"Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-2116","authenticated-orcid":false,"given":"Paula","family":"Jab\u0142onowska-Babij","sequence":"additional","affiliation":[{"name":"Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-2903","authenticated-orcid":false,"given":"Marta","family":"Morawska","sequence":"additional","affiliation":[{"name":"Experimental Hematooncology Department, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[{"name":"Department of General Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Szukalski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 85-168 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4476-9703","authenticated-orcid":false,"given":"Judyta","family":"Strza\u0142a","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals in Gdynia, 81-519 Gdynia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Gosik","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. John\u2019s Cancer Center in Lublin, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"D\u0119bski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Provincial Specialist Hospital in Legnica, 59-220 Legnica, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-8758","authenticated-orcid":false,"given":"Iga","family":"Andrasiak","sequence":"additional","affiliation":[{"name":"Individual Business Activity, ul. Zielna 28b\/3, 51-313 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-0572","authenticated-orcid":false,"given":"Anna","family":"Skotny","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health\u2014Executive and Continuing Education, Harvard University, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[{"name":"Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5603\/ahp.97472","article-title":"Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists, and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2023","volume":"54","author":"Hus","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Al-Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y.M., Fink, A.M., Tausch, E., Schneider, C., Ritgen, M., and Kreuzer, K. (2023, January 13\u201317). Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Proceedings of the 17th International Conference on Malignant Lymphoma, Lugano, Switzerland.","DOI":"10.1097\/01.HS9.0000843484.72409.00"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-023-05304-4","article-title":"Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group","volume":"102","author":"Morawska","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/ajh.27247","article-title":"Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study","volume":"99","author":"Autore","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11912-022-01261-9","article-title":"Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies","volume":"24","author":"Rivera","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","first-page":"5187","article-title":"Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: A representative analysis of guideline adherence and infections","volume":"30","author":"Link","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101180","DOI":"10.1016\/j.blre.2024.101180","article-title":"Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines","volume":"65","author":"Mikulska","year":"2024","journal-title":"Blood Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3324\/haematol.2016.150706","article-title":"Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia","volume":"102","author":"Strati","year":"2017","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/cncr.11736","article-title":"Pulmonary complications in chronic lymphocytic leukemia","volume":"98","author":"Ahmed","year":"2003","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2174\/1573405618666220509212035","article-title":"The Relationship among Splenomegaly, Lung Involvement Patterns, and Severity Score in COVID-19 Pneumonia","volume":"18","author":"Aksu","year":"2022","journal-title":"Curr. Med. Imaging Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4046\/trd.2018.0030","article-title":"Pneumonia in Patients with Chronic Obstructive Pulmonary Disease","volume":"81","author":"Restrepo","year":"2018","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/COPD.S142530","article-title":"Predictors of pneumonia on routine chest radiographs in patients with COPD: A post hoc analysis of two 1-year randomized controlled trials","volume":"13","author":"Rubin","year":"2018","journal-title":"Int. J. Chron. Obs. Pulmon. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2023-181037","article-title":"Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study","volume":"142","author":"Autore","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Reade, M.C., Weissfeld, L., Angus, D.C., Kellum, J.A., and Milbrandt, E.B. (2010). The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia. BMC Pulm. Med., 10.","DOI":"10.1186\/1471-2466-10-15"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Veronese, N., Segala, F.V., Carruba, L., La Carrubba, A., Pollicino, F., Di Franco, G., Guido, G., Cormio, M., Lugli, A., and De Santis, L. (2023). Anemia as a risk factor for disease progression in patients admitted for COVID-19: Data from a large, multicenter cohort study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36208-y"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.52547\/ibj.3703","article-title":"On-admission anemia and survival rate in COVID-19 patients","volume":"26","author":"Asadzadeh","year":"2022","journal-title":"Iran. Biomed. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102926","DOI":"10.1016\/j.transci.2020.102926","article-title":"Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection","volume":"59","author":"Hariyanto","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chisti, M.J., Kawser, C.A., Rahman, A.S.M.M.H., Shahid, A.S.M.S.B., Afroze, F., Shahunja, K.M., Shahrin, L., Sarmin, M., Nuzhat, S., and Rahman, A.E. (2022). Prevalence and outcome of anemia among children hospitalized for pneumonia and their risk of mortality in a developing country. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14818-2"}],"updated-by":[{"DOI":"10.3390\/cancers17122032","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"record-id":"66289"},{"DOI":"10.3390\/cancers17122032","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000}}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:52:25Z","timestamp":1754232745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":21,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244168"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244168","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}